10-Hydroxy-HHCP
 | |
| Identifiers | |
|---|---|
IUPAC name
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C23H36O3 |
| Molar mass | 360.538 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
10-Hydroxy-HHCP (10-Hydroxy-hexahydrocannabiphorol) is a semi-synthetic cannabinoid which has been sold as a designer drug, first identified in Germany in December 2024.[1]
See also
References
- ↑ "European Drug Report 2025 – Full Book" (PDF). European Union Drugs Agency (euda.europa.eu). 6 June 2025.
| Phytocannabinoids (comparison) |
| ||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||
| Synthetic cannabinoid receptor agonists / neocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||
| Allosteric CBRTooltip Cannabinoid receptor ligands | |||||||||||||||||||||||||||||||||||||||||
| Endocannabinoid enhancers (inactivation inhibitors) |
| ||||||||||||||||||||||||||||||||||||||||
| Anticannabinoids (antagonists/inverse agonists/antibodies) |
| ||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||
This article is issued from WikiProjectMed. The text is available under Creative Commons Attribution-ShareAlike License unless otherwise noted. Additional terms may apply for the media files.